次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

ワクチン製造技術と受託製造サービス(CMO)の世界市場2014-2024年

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024
Prospects For Leading Players

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年3月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文205ページになります。
商品コード:VGN187

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
Visiongain社の調査によれば、ワクチン受託製造サービスの世界市場は2014年に7億562万ドルに達すると推計され、2014年から2024年にかけて力強い成長が見込まれます。当レポートでは同市場の2024年に至る市場予測、詳細なセグメント別予測分析に加え、市場動向、リーディング企業情報などを概略以下の構成でお届けしています。

【レポート構成概要】
・ワクチン受託製造サービスの世界市場予測2014年-2024年
・全205ページ、104個のデータ表、グラフ類で市場を詳細分析、定量化
・業界専門家オピニオンインタビュー:
- Dr. Eluemuno Blyden, CEO and Founder, AfriVax
- Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
- Dr. Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
- Dr. Stefan Beyer, Managing Director, Vibalogics

・主要5セグメント別市場予測2014-2024年
- 小児ワクチンPaediatric vaccines
- インフルエンザワクチンInfluenza vaccines
- 予防ワクチンAdult prophylactic vaccines
- 治療用ワクチンTherapeutic vaccines
- ワクチン受託製造Contract vaccine manufacturing

・主要11ヶ国、国別市場予測2014-2024年VGN187_Vaccine Manufacturing Technology and Services World Market Forecast 2014-2024 Cover.jpgレポート表紙
- 米国
- 日本
- ドイツ
- イタリア
- スペイン
- フランス
- 英国
- ロシア
- 中国
- インド
- ブラジル
- その他RoW

・リーディング企業10社プロフィール。活動、将来展望、主要製品、新製品、業績、M&A、提携等
- Baxter BioPharma Solutions
- Boehringer Ingelheim
- Catalent
- Charles River Laboratories
- IDT Biologika GmbH
- Lonza
- Meridian Life Science
- Sigma-Aldrich
- SynCo Bio Partners
- OSO BioPharmaceuticals Manufacturing

・市場動向分析(諸論点)
- ワクチン製品のパイプラインHealthy pipeline of vaccine products
- 細胞ベース技術Cell-based techniques - mammalian cell lines, avian-derived cells, plant-based processes and other methods
- パンデミック対策Pandemic preparedness
- 価格、規制、政策Pricing, regulation and government policy
- ワクチン委託製造にリスクがあるという認知Perception of risk in outsourcing vaccine manufacturing

Visiongain is a trading partner with the US Federal Government
【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024

Table of Contents

1. Executive Summary

1.1 Overview
1.2 Review of the Vaccine Manufacturing Technology and Services Market
1.3 Aims, Scope and Format of Report
1.4 Research and Analysis Methods

2. Introduction to the Vaccine Market

2.1 What Are Vaccines?
2.2 The History of the Vaccine Market
2.3 The Vaccine Contract Manufacturing Market
2.3.1 Outsourcing in the Pharmaceutical and Biotechnology Industry
2.3.2 Reasons to Outsource
2.3.3 Benefits of Outsourcing
2.3.4 The Challenges in Outsourcing Vaccine Manufacturing
2.3.5 Why Should Companies Outsource Vaccine Manufacturing?
2.3.6 Strategic Outsourcing vs. Tactical Outsourcing
2.3.7 Virtual Companies
2.3.8 Contract Manufacturing Organisations (CMOs)
2.3.9 Manufacturing Services Offered by CMOs
2.3.10 Vaccine Manufacturing Activities Typically Outsourced

3. Vaccine Manufacturing Technologies 2014

3.1 Summary of Vaccine Technology Trends
3.2 New Substrates for Vaccine Production
3.2.1 Shift Towards Cell-Based Manufacturing Technology
3.2.2 Benefits of Cell-Based Techniques
3.2.3 Mammalian Cell Lines
3.2.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.2.3.2 Vero Cells
3.2.3.3 PerC6 Cells
3.2.4 Avian-Derived Cell Lines
3.2.4.1 EB66 Stem Cell Technology: Vivalis
3.2.5 Plant-Based Vaccines
3.2.5.1 Medicago's Proficia VLP Vaccine Technology
3.2.6 Insect Egg-Based Production Systems
3.2.6.1 Novavax's Sf9/BV Technology
3.2.6.2 Protein Sciences Corporation (PSC): First Egg-Free Influenza Vaccine
3.3 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.3.1 AdVac Technology: Crucell
3.3.2 AdCEV Vectors: AfriVax
3.3.3 Pfenex Expression Technology: Pfenex
3.4 Equipment Trends
3.4.1 The Shift Towards Disposable Single-use Equipment
3.4.2 Bioreactors and Vaccine Production
3.4.2.1 Single-Use Bioreactors
3.4.2.2 Main Applications of Disposable Bioreactors
3.4.2.3 Current Single-Use Bioreactor Systems on the Market
3.5 Prefilled Syringes and Vaccines
3.5.1 Growing Market for Pre-Filled Syringes
3.5.2 Leading Pre-Filled Vaccine Products 2014
3.5.3 Drivers and Restraints for Pre-filled Syringes
3.5.4 Product Stability and Quality Assurance Programme
3.5.4.1 Paediatric H1N1 Vaccine
3.5.4.2 Reported Challenges with Some Flu Vaccine
3.5.4.3 Novartis' Agriflu and Fluad Ban is Lifted
3.5.4.4 Baxter Flu Vaccine and Side Effects
3.5.4.5 Reported Shelf Life Issues of Some H1N1 Vaccine
3.6 Lyophilisation and Vaccine Manufacturing
3.7 Cell Media Can Improve Virus Yield

4. The Vaccine Market 2014-2024

4.1 The Global Vaccine Market, 2014-2024
4.2 The Global Vaccine Market By Submarket, 2012 and 2013
4.3 The Global Vaccine Market by Submarket, 2014-2024
4.4 The Paediatric Vaccine Submarket Forecast, 2014-2024
4.4.1 Growth of Paediatrics Vaccines is Driven by Prevnar's Blockbuster Success
4.4.2 Paediatric Vaccines: The Biggest Segment, but the Least Dynamic
4.4.3 Paediatric Vaccine Pipeline
4.5 The Adult Prophylactic Vaccine Submarket Forecast, 2014-2024
4.5.1 Adult Vaccination: Low Uptake
4.5.2 Gardasil Represented Nearly a Fifth of Segment Revenues in 2012
4.5.3 Adult Prophylactic Vaccines: Extensive Pipeline, but Still Needs to Become More Widely Established
4.5.4 Adult Prophylactic Vaccine Pipeline
4.6 The Influenza Vaccine Submarket, 2014-2024
4.6.1 Influenza: Growth is Driven by Seasonal Epidemics and Global Pandemics
4.6.2 Significant Scope for Enlarging the Patient Population
4.6.3 Influenza Market: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
4.6.4 Influenza Product Pipeline
4.7 The Therapeutic Vaccine Submarket, 2014-2024
4.7.1 Therapeutic Vaccines: the Holy Grail of Personalised Vaccines
4.7.2 Therapeutic Vaccines: On the Cusp of an Explosion or Another Vaccine Hype?
4.7.2.1 Underperformance: Provenge is the First and Only FDA Approved Cancer Vaccine
4.7.2.3 Biovac ID Completes Phase III for Cancer Vaccine
4.7.3 Anti-Allergy Vaccines Make Up Bulk of Segment in 2013
4.7.3.1 Canada Gives Merck & Co. its First Approval for Grass Allergy Vaccine Tablet
4.7.3.2 Therapeutic Vaccine Product Pipeline

5. The Global Vaccine Contract Manufacturing Market 2014-2024

5.1 Global Vaccine Contract Manufacturing: A Tiny Fraction of The Total Vaccine Market
5.2 The Vaccine Contract Manufacturing Market Forecast: High Growth Rates from 2014-2024
5.2.1 Trends in the Vaccine Contract Manufacturing Forecast
5.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.3.1 The Leading National Markets for Vaccine Contract Manufacturing: Largely Dictated by the Local Vaccine Market
5.3.2 The Leading National Markets for Vaccine Contract Manufacturing, 2012 and 2013
5.3.3 The Leading National Markets for Vaccine Contract Manufacturing, 2014-2024
5.4 The US Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5 The Japanese Vaccine Contract Manufacturing Market Forecast, 2014-2024
5.5.1 CMO's in Japan
5.6 The EU5 Vaccine Contract Manufacturing Market, 2012 and 2013
5.6.1 The EU5 Vaccine Contract Manufacturing Market, 2014-2024
5.6.2 The French Vaccine Contract Manufacturing Market, 2014-2024
5.6.3 The German Vaccine Contract Manufacturing Market, 2014-2024
5.6.4 The Italian Vaccine Contract Manufacturing Market, 2014-2024
5.6.5 The Spanish Vaccine Contract Manufacturing Market, 2014-2024
5.6.6 The UK Vaccine Contract Manufacturing Market, 2014-2024
5.7 The Brazilian Vaccine Contract Manufacturing Market, 2014-2024
5.8 The Russian Vaccine Contract Manufacturing Market, 2014-2024
5.9 The Indian Vaccine Contract Manufacturing Market, 2014-2024
5.10 The Chinese Vaccine Contract Manufacturing Market, 2014-2024
5.10.1 Vaccine Manufacturing: Questioning China's Regulatory Standards

6. The Leading Vaccine Contract Manufacturing Companies 2014-2024

6.1 The Vaccine Contract Manufacturing Market has Room for Consolidation
6.2 Baxter BioPharma Solutions
6.2.1 Business Capabilities
6.3 Boehringer Ingelheim
6.3.1 Recent Financial Performance
6.3.2 Boehringer Ingelheim's Ben Venue Closure
6.3.3 Manufacturing Deals 2011-2014
6.3.4 Boehringer Ingelheim Implements Fully Disposable Biopharmaceutical Manufacturing
6.3.5 Boehringer Ingelheim Expands Biopharmaceuticals in China
6.3.6 Outlook
6.4 Catalent
6.4.1 Recent Financial Performance, 2008-2012
6.4.2 Recent Financial Performance by Segment, 2008-2012
6.4.3 Catalent Injectable Vaccines
6.4.4 Catalent Adjusts its Services
6.4.5 Future Strategies for Growth
6.4.6 Regional Market Expansion
6.5 Charles River Laboratories
6.5.1 Recent Financial Performance, 2008-2012
6.5.2 Recent Financial Performance, 3Q 2013
6.5.3 Recent Financial Performance by Segment
6.5.4 Vaccine Manufacturing Services
6.5.4.1 Vaccine Manufacturing Expansion
6.5.5 Future Outlook and Early Stage Restructuring
6.5.6 Partnerships
6.5.6.1 Partnership with AstraZeneca
6.5.6.2 Partnership with Batavia
6.6 IDT Biologika GmbH
6.6.1 Facility Expansion
6.6.2 Acquisitions and Partnerships
6.6.2.1 Acquisition of Riemser Pharma GmbH
6.6.2.2 Partnership with ImVisioN Therapeutics
6.7 Lonza
6.7.1 Recent Financial Performance, 2010-2012
6.7.1.1 Recent Financial Performance by Segment,2012
6.7.2 Manufacturing Division Restructuring
6.8 Meridian Life Science
6.8.1 Recent Financial Performance, 2008-2013
6.8.1.1 Recent Financial Performance by Segment, 2008-2013
6.8.1.2 Recent Financial Performance by Region, 2012-2013
6.9 Sigma-Aldrich
6.9.1 Revenue and Recent Performance Analysis, 2010-2013
6.9.1.1 Recent Financial Performance by Segment, 2010-2012
6.9.1.2 Segment restructuring, 2013
6.9.2 Strategy for Business Growth by Asian Expansion
6.9.3 Acquisition of BioReliance
6.9.4 Partnership with CatScl
6.10 SynCo Bio Partners
6.10.1 Recent Developments
6.10.1.1 Expansion of Facilities
6.10.1.2 FDA Approval of Partner Application
6.11 OSO BioPharmaceuticals Manufacturing
6.11.1 Facilities and Capabilities
6.11.2 New Developments
6.11.2.1 Acquisition of Catalent's Sterile Injectables Manufacturing Business
6.11.2.2 Facility Investment
6.12 Leading Vaccine Contract Manufacturing Organisations

7. SWOT Analysis of the Vaccine Contract Manufacturing Market 2014-2024

7.1 Vaccine Contract Manufacturing Industry Trends
7.2 Strengths
7.2.1 Many Companies Cannot Afford In-house Capabilities
7.2.2 Outsourcing Improves Time to Market
7.2.3 Manufacturers get Access to Specialised Technologies
7.2.4 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
7.3 Weaknesses
7.3.1 Mass Vaccine Manufacturing is Kept In-house
7.3.2 A Highly Fragmented Vaccine Contract Manufacturing Market
7.3.3 An Unpredictable Supply and Demand Business Model
7.3.4 Lack of Differentiation in the CMO Space
7.4 Opportunities
7.4.1 Many Vaccines in the Product Pipeline
7.4.2 Therapeutic Vaccine Market could Explode
7.4.3 Emerging Market's Growing Demand for Vaccines
7.4.3.1 Dynamic Change: Emerging Markets are Major Vaccine Developers
7.5 Threats
7.5.1 Post Recession: Biotech Suffer from Severe Cuts in Capitalist Funding
7.5.2 The Public are Slow to Accept Novel Technologies
7.5.3 Perception of Risk by the Original Vaccine Manufacturers

8. Expert Opinion

8.1 Interview with Dr. Eluemuno Blyden, CEO and Founder, AfriVax
8.1.1 The Egg-based Vaccine Manufacturing Myth
8.1.2 AfriVax's New Vaccine Manufacturing Technology
8.1.3 Emerging Markets Pathing their Own Vaccine Path
8.2 Interview with Chris Redmond, GMP and nonGMP Sales Manager, Ambiopharm
8.2.1 Growth of the Vaccine Contract Manufacturing Market
8.2.2 The Therapeutic Vaccine Market
8.2.3 The Use of Emerging Market Facilities
8.2.4 The Vaccine Contract Manufacturing Business Model
8.3 Interview with Dr Victor Van Cleave, Vice President of Contract Manufacturing & Research and Development (R&D), Meridian Life Science
8.3.1 Vaccine Contract Manufacturing Competition
8.3.2 Target Diseases For Vaccine Development
8.3.3 Challenge Stock Vaccines
8.3.4 Meridian's Vaccine Contract Manufacturing Revenue Stream Breakdown
8.3.5 The Changing Face of Large Pharma Drives Contract Manufacturing Growth
8.4 Interview with Dr Stefan Beyer, Managing Director, Vibalogics
8.4.1 The Benefits of Outsourcing Vaccine Manufacturing
8.4.2 The Challenges in Manufacturing Vaccines

9. Conclusion

9.1 Overview
9.2 Regulatory and Quality Standards Create High Barriers of Entry
9.3 Rich Pipeline for Therapeutic Vaccines
9.4 Emerging Markets will Show Stronger Growth
9.5 Technology Drives Changes in Manufacturing

List of Tables

Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD - Present
Table 3.1 Vaccine Development Pipeline Using Protein Sciences Corporation's BEVS Vaccine Technology, 2014
Table 3.2 Vaccine Development Pipeline Using Crucell's AdVac Technology, 2014
Table 3.3 Benefits and Drawbacks of Using Disposable Technology for Vaccine Production, 2014
Table 3.4 Companies Providing Disposable Biomanufacturing Platforms/Systems, 2014
Table 3.5 Some Leading Pre-Filled Syringe Vaccine Products, 2014
Table 3.6 Prominent Lyophilised Vaccines, 2014
Table 3.7 Examples of Serum-free Media for Vaccine Manufacturing, 2014
Table 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.2 The Global Vaccine Market: Revenue ($bn), Market Share by Submarket (%), 2012-2013
Table 4.3 The Global Vaccine Market by Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.4 The Paediatric Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.5 Selected Pipeline Vaccines in Paediatric Submarket, 2014
Table 4.6 The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.7 Selected Pipeline Vaccines in Adult Prophylactic Submarket, 2014
Table 4.8 The Influenza Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.9 Selected Pipeline Vaccines in Influenza Submarket, 2014
Table 4.10 The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%), CAGR (%) 2012-2024
Table 4.11 Selected Pipeline Vaccines in Therapeutic Submarket, 2014
Table 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.2 The Leading National Vaccine Contract Manufacturing Markets Forecast: Revenue ($m), Market Share (%), 2012-2013
Table 5.3 The Leading National Vaccine Contract Manufacturing Markets Forecasts: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.4 The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.5 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.6 The EU5 National Vaccine Contract Manufacturing Markets: Revenue ($m), Market Share (%) by Country, 2012-2013
Table 5.7 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.8 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.9 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.10 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.11 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.12 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.13 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.14 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.15 The Indian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.16 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.1 Baxter BioPharma Solutions Capabilities, 2014
Table 6.2 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
Table 6.3 Catalent: Offerings and Services by Segment, 2014
Table 6.4 Catalent: Revenue($m), AGR (%), 2008-2012
Table 6.5 Catalent by Segment: Revenue($m), AGR (%), 2011-2012
Table 6.6 Charles River Laboratories: Services Provided by Segment, 2014
Table 6.7 Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
Table 6.8 Charles River Laboratories: Pre-clinical Services Segment Revenue ($m), 3Q 2012-2013
Table 6.9 Charles River Laboratories: Revenue ($bn) by Segment, 2009-2012
Table 6.10 Charles River Laboratories: cGMP Vaccine Manufacturing and Testing Capabilities, 2014
Table 6.11 IDT: Work Units in the Vaccine Production Line
Table 6.12 Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
Table 6.13 Lonza: Revenue ($bn), Market Share (%) by Segment, 2012
Table 6.14 Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
Table 6.15 Meridian Bioscience: Revenue ($m), AGR (%) by Segment, 2010-2013
Table 6.16 Meridian Life Science: Revenue ($m), AGR (%) by Region, 2012-2013
Table 6.17 Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2012
Table 6.18 Sigma Aldrich: Revenue ($bn) by Segment, 2010-2012
Table 6.19 SynCo's Capabilities, 2014
Table 6.20 Leading Vaccine Contract Manufacturing Organisations, 2014
Table 7.1 SWOT Analysis of the Vaccine Contract Manufacturing Market, 2012-2024

List of Figures

Figure 2.1 Selected Tasks Outsourced in the Pharmaceutical and Biotech Industry, 2014
Figure 3.1 Influenza Vaccine Production Using a Cell-Based Manufacturing Method, 2014
Figure 3.2 Medicago's Product Pipeline, 2014
Figure 3.3 Novavax' Insect Egg-Based Vaccine Production Process, 2014
Figure 3.4 Novavax's Product Pipeline, 2014
Figure 3.5 Single-Use Bioreactors Market, 2012
Figure 3.6 Pre-filled Syringes Market: Drivers and Restraints, 2014-2024
Figure 4.1 The Global Vaccine Market Forecast: Revenue ($bn), AGR (%) 2012-2024
Figure 4.2 The Global Vaccine Market: Market Share by Submarket (%), 2013
Figure 4.3 The Paediatric Vaccine Market: Revenue ($bn), AGR (%), 2012-2024
Figure 4.4 The Adult Prophylactic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 4.5 The Influenza Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 4.6 The Therapeutic Vaccine Submarket: Revenue ($bn), AGR (%) 2012-2024
Figure 5.1 The Global Vaccine Contract Manufacturing Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.2 The Leading National Vaccine Contract Manufacturing Markets: Revenue (%) by region, 2013
Figure 5.3 The US Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 5.4 The Japanese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 5.5 The EU5 Vaccine Contract Manufacturing Markets: Revenue (%) by Country, 2013
Figure 5.6 The EU5 Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.7 The French Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.8 The German Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.9 The Italian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.10 The Spanish Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.11 The UK Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.12 The Brazilian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.13 The Russian Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.14 The Indian Vaccines Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.15 The Chinese Vaccine Contract Manufacturing Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 6.1 Boehringer Ingelheim: Typical Contract Manufacturing Process, 2014
Figure 6.2 Boehringer Ingelheim: Biopharmaceuticals Revenue ($m), 2011-2012
Figure 6.3 Catalent: Revenue ($m), AGR (%), 2008-2012
Figure 6.4 Catalent: Market Share (%) by Segment, 2012
Figure 6.5 Charles River Laboratories: Revenue ($bn), AGR (%), 2008-2012
Figure 6.6 Charles River Laboratories: Revenue ($bn), AGR (%), 3Q 2012-2013
Figure 6.7 Charles River Laboratories: Market Share (%) by Segment, 2012
Figure 6.8 Lonza Custom Manufacturing: Revenue ($bn), AGR (%), 2010-2012
Figure 6.9 Lonza: Market Share (%) by Segment, 2012
Figure 6.10 Meridian Bioscience: Revenue ($m), AGR (%), 2008-2013
Figure 6.11 Meridian Bioscience: Revenue ($m) by Segment, 2010-2013
Figure 6.12 Meridian Bioscience: Market Share (%) by Segment,2013
Figure 6.13 Meridian Life Science: Market Share by Region, 2013
Figure 6.14 Sigma Aldrich: Revenue ($bn), AGR (%), 2010-2013
Figure 6.15 Sigma Aldrich: Market Share (%) by Segment, 2012
Figure 6.16 Sigma Aldrich: Market Share (%) by Segment, 2013
Figure 7.1 Vaccines in the Pipeline, Phase 1-3
Figure 7.2 Drivers and Restraints for the Vaccine Contract Manufacturing Sector, 2014-2024
Figure 9.1 Vaccine & Vaccine Contract Manufacturing Market: AGR(%), 2012-2024
Figure 9.2 Therapeutic Vaccines in the Pipeline, Phase 1-3

掲載企業リスト

Companies Listed

AAI Pharma Services Corp.
AbbVie
Accugenix
Activaris Biotech
Adamis Pharmaceuticals
Aduro Biotech
Advanced Bioscience Laboratories, Inc.
Advaxis
AFFiRis
Afrivax
Agenus
ALK- Abello
Alpha Biologics
AlphaVax
Althea Technologies, Inc.
Ambiopharm
Amgen
AmProtein
Antigen Express
Antigenics
Aptuit CTS
Argos Therapeutics
Artelis
AstraZeneca
ATMI
ATMI LifeSciences
AuRx
Avista Capital Partners
Batavia
Bavarian Nordic
Baxter
Baxter BioPharma Solutions
Bayer
Bayer Healthcare
Bayhill Therapeutics
Beijing Tiantan Biological Products
Bellicum Pharmaceuticals
Ben Venue Laboratories
Bend Research
Berna Biotech
Bharat Biotech International
Binnopharm
Biofabri
BioKangtai
Biological E. Serum Institute
Biomay
Biondvax
Bionor Pharma
BioReliance
BioSante Pharmaceuticals
Biovest International
Biovian
BN ImmunoTherapeutics
Boehringer Ingelheim
Bosch
Cadila Pharmceuticals
Cancer Advances
Cardinal Health
Catalent
Catalent (Shanghai) Clinical Trial Supplies
Catalent Pharma Solutions
CatScl
Celldex Therapeutics
Cellexus Limited
CEL-SCI
Celtic Pharma
Cerebricon
CG Therapeutics
Charles River Biopharmaceutical Services
Charles River Laboratories
Chengdu Institute of Biological Products
China National Biotech Corporation
Chiron B.V
Circassia
CMC Biologics
Cobra Biologics
Colby Pharmaceutical
Cook Pharmica
Corden Pharma
Covance
Crucell
CSL Biologicals
Cytos Biotechnology
Cytovance Biologics
Daiichi Sankyo
Dalian Hissen Bio-Pharm
DBV Technologies
Dendreon
DSM Biologics
Dynport Vaccine
EMD Serono
Emergent BioSolutions
Endocyte
Etubics
Eurogentec Biologics
FiberCell
Frazier Healthcare
Fujifilm Diosynth Biotechnologies
Galena
Gcon
GE Healthcare Life Sciences
GE Wave Biotech
GeneCure Biotechnologies
Genetic Immunity
Genocea Biosciences
GenPhar
GenVec
GeoVax
GlaxoSmithKline Biologicals
Gliknik
Globelmmune
Goodwin Biotechnology Inc.
Gradalis
Grand River Aseptic Manufacturing
GSK
Hawaii Biotech
Heat Biologics
Hospira
HTD Biosystems
iBio
IDT Biologika GmbH
immatics biotechnologies
Immune Response Biopharma
Immune Targeting Systems
Immunitor
ImmunoCellular Therapeutics
ImmunoFrontier
Immunomic Therapeutics
Immunotope
Immunovaccine
Immunovative Therapies
ImmunsanT
ImVisioN Therapeutics
Innogenetics Biologicals
Inovio Pharmaceuticals
Intercell Corporation
Inviragen
Invitrogen
Irvine Scientific
Janssen Alzheimer Immunotherapy
Japan Vaccine Co
Jennerex
JHP Pharmaceuticals
JN-International Medical
Johnson & Johnson
Jubilant HollisterStier
Kuhner
Leidos
LG Life Sciences
LigoCyte Pharmaceuticals
Liquidia Technologies
Lonza
MabVax Therapeutics
Medicago
MedImmune
Meisser Filtration
Memgen
Merck
Merck Serono
Meridian Life Science
Millipore
Mitsubishi Tanabe Pharma
MorphoSys
MP Biomedicals
NanoBio
Nanotherapeutics
Nascent Biologics
NewLink Genetics
Northwest Biotherapeutics
Novadigm Therapeutics
Novartis
Novartis Vaccines and Diagnostics
NovaRX
Novasep
Novavax
OncoPep
Oncothyreon
Opal Therapeutics
Opexa Therapeutics
Optimer Biotechnology
Orban Biotech
Organon Teknika Corporation
OSO Biopharmaceuticals Manufacturing
Pall Life Sciences
Pantec
Paragon Bioservices
Patheon
PaxVax
PBS Biotech
Penn Pharma
Pfizer (Wyeth Pharmaceuticals)
Pfrenex
PharmAthene
Philip Morris International
Piedmont Research Center
Pierre-Guérin Biolafitte
Pique Therapeutics
Polynoma
Prima Biomed
ProBioGen
Profectus BioSciences
Protein Sciences Corporation
Rame-Hart Sanovo
Refine Technology
Riemser Pharma GmbH
Roche
SAFC
Sanaria
Sanofi Pasteur
Sanofi Pasteur MSD
Sartorius Stedim Biotech
Selecta Biosciences
Selecta RUS
Shanghai Sunway Biotech
ShangPharma Corporation
Shantha Biotech
Sigma Aldrich
Soligenix
Stallergenes
Stemline Therapeutics
Sumagen
Sunovion Pharmaceuticals
Synco Bio Partners
Takeda
TapImmune
TD Vaccines
Theraclone Sciences
Thermo Fisher scientific
Thymon
Transgene
TVAX Biomedical
United Biomedical
Vaccine Technologies
Vaccinogen
Vaxart
VaxInnate
VaxOnco
Vibalogics
Vivalis
Waisman Biomanufacturing
Wave Biotech
Xcellerex
Xencor
ZellWerk
Zhangjiang Biotech & Pharmaceutical Base
Zhejiang Jiang Yuan Tang Biotechnology Corporation

Other Organisations Mentioned in This Report

Aaron Diamond AIDS Research Center
Aeras Global TB Vaccine Foundation
Agência Nacional de Vigilância Sanitária (ANVISA)
Centers for Disease Control and Prevention CDC (US)
Chinese State Food and Drug Administration (SFDA)
Defense Advanced Researched Projects Agency (DAPRA)
Emory University
European Medicines Agency (EMA)
Executive European Commission (European Union)
Health Canada
Hospital Clínic de Barcelona
Infectious Disease Research Institute (IDRI)
International AIDS Vaccine Initiative (IAVI)
Ministry of Industry and Trade (Russia)
Murdoch Childrens Research Institute
National Institute of Health (US)
PATH
Research Foundation for Microbial Diseases of Osaka University
The Department of Health and Human Services (HHS) (US)
The Drug Enforcement Administration (DEA) (US)
The Food and Drug Administration (FDA) (Korean)
The Food and Drug Administration (FDA) (US)
The National Institute of Allergy and Infectious Diseases (NIAID)
The U.S. Department of Health and Human Services Office of Biomedical Advanced Research and Development Authority (BARDA)
The United Nation Industrial Development Organisation (UNIDO)
US Naval Medical Research Center
Vaccine Manufacturers Associations (India)
World Health Organisation (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。